Clinical Trial

Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP

Study acronym: iGP3-SWITCH
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if the genetically-modified malaria parasite NF54/iGP3 will safely infect humans with malaria. The investigators will also determine how the parasite grows in humans, and the effect of anti-malarial drugs. Researchers will use a controlled human malaria infection (CHMI) model to infect participants with malaria to observe the development of the disease, collect malaria-infected blood, and then treat the participants to cure the malaria infection. The collected malaria-infected blood will be used to create a frozen stock of malaria parasites for use in future research.
Trial Details
NCT Number NCT06881732
Lead Sponsor University of Melbourne
Collaborators: Walter and Eliza Hall Institute of Medical Research, Swiss Tropical & Public Health Institute, QIMR Berghofer Medical Research Institute
Conditions Malaria Falciparum, Malaria Infection, Malaria Transmission
Enrollment 2 participants
Start Date 2025-07
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-18